MHRA recall M&A Pharmachem’s paracetamol due to fungal contamination
pharmafile | June 18, 2019 | News story | Manufacturing and Production | Contamination, MHRA, fungal, paracetamol, pharma
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a recall of M&A Pharmachem’s 500mg paracetamol tablets.
The tablets, which were produced in two separate batches of one thousand each, were found to be contaminated with the fungi Penicillium citrinium and Penicillium brevicompactum.
A number of tablets in each batch were found to be discoloured due to the fungal contamination.
However officials believe that patients have not taken the drugs as the discolouration is noticeable on opening the pack.
Wholesalers and healthcare professionals have been advised to stop supplying the affected batches as a quarantine has been put in place so that any remaining stock can be sent back to the supplier.
Louis Goss
Related Content
MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment
Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing …
MHRA approves GSK’s Omjjara in Great Britain for splenomegaly treatment
GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing …
MHRA approves Mounjaro for diabetes and weight management
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that it has approved a …